Athersys logo
Athersys ATHX
report update icon

Quarterly report 2023-Q3
added 06-27-2026

Athersys Financial Ratios 2022-2008 | ATHX

Brief overview of Athersys's valuation and returns

This overview follows the five latest available observations from 2009 through 2022.

Market valuation is represented by EV/EBITDA 0.12x (median 0.19x), P/S 1.46x (median 10.62x), P/B 0.13x (median 4.72x). Valuation is roughly 61.2% below five-year reference levels. The discount may reflect opportunity or higher perceived risk.

The latest available business-quality ratios are ROE 3%, ROA -2.6%, ROCE 3.2%. Current return ratios are negative, materially weakening the fundamental profile.

PEG is 1.01x. Price relative to expected growth is in a moderate range.

The cash cycle lengthened by 66.6 days to 73 days. Operations require more funding.

Overall assessment

Athersys trades below its own history, but weak profitability may explain the discount. Low multiples alone do not prove undervaluation.

Annual Financial Ratios Athersys

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

P/E

- -0.1 -0.2 -4.1 -8.4 -4.8 -6.6 -8.9 -9.0 -7.1 -3.4 -3.4 - - -

P/S

- 1.5 10.6 32.3 8.4 41.4 5.9 12.2 122.8 89.4 5.7 4.5 - - -

EPS

-6.1 -9.7 -10.5 -0.3 -0.2 -0.1 -0.1 -0.2 -0.3 -0.5 -0.5 -0.6 -0.6 -0.8 -

EV (Enterprise Value)

-9.04 M -29.3 M -7.9 M 165 M 171 M 134 M 94.8 M 129 M 181 M 200 M 31.6 M 46.6 M -2.1 M -11.2 M -12.6 M

EBITDA per Share

-6.33 -9.55 -10.3 -0.3 -0.18 -0.29 -0.17 -0.21 -0.37 -0.42 -0.48 -0.58 -0.59 - -

EV/EBITDA

0.1 0.3 0.1 -3.7 -7.1 -4.1 -6.5 -7.6 -6.3 -8.3 -2.0 -3.4 0.2 0.7 -

PEG

- -0.0 -0.0 -0.55 1.01 1.48 0.32 0.51 -0.16 0.41 -0.13 -1.89 - - -

P/B

- 0.1 0.5 7.8 4.7 6.6 9.1 7.4 9.5 11.0 2.5 6.4 - - -

P/CF

- -0.1 -0.2 -5.2 -15.3 -6.4 -9.3 -6.9 -6.2 -9.6 -2.8 -3.2 - - -

ROE %

304.11 -531.22 -251.15 -191.58 -56.32 -137.92 -137.17 -83.26 -105.68 -155.10 -72.78 -188.35 -126.34 -81.06 -

ROA %

-261.56 -144.48 -131.90 -107.00 -39.34 -95.98 -80.47 -65.35 -76.89 -89.92 -53.38 -87.55 -59.55 - -

ROCE %

322.88 -531.85 -213.09 -157.79 -54.15 -141.57 -123.32 -84.28 -120.75 -82.02 -69.19 -166.41 -127.83 -82.37 -

Current Ratio

- - 2.1 2.3 3.3 3.3 2.4 4.6 3.7 2.4 3.8 1.9 - - -

DSO

73.0 46.8 22.6 8.5 6.4 58.3 10.1 16.1 136.5 75.6 24.7 53.2 - - -

Operating Cycle

73.0 46.8 22.6 8.5 6.4 58.3 10.1 16.1 136.5 75.6 24.7 53.2 - - -

Cash Conversion Cycle

73.0 46.8 22.6 8.5 6.4 58.3 10.1 16.1 136.5 75.6 24.7 53.2 - - -

All numbers in USD currency

Quarterly Financial Ratios Athersys

2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-0.15 -0.62 -0.43 - -1.15 -90 -0.09 -0.09 -0.07 -0.1 -0.13 -0.11 -0.11 -0.1 -0.1 -0.06 -0.08 -0.06 -0.09 -0.08 -0.07 0.05 -0.08 -0.11 -0.06 -0.06 -0.06 -0.08 -0.07 -0.08 0.06 0.04 -0.08 -0.01 -0.16 -0.08 -0.06 0.01 -0.15 -0.15 -0.1 -0.11 -0.18 -0.07 -0.12 -0.13 -0.17 -0.18 -0.1 -0.14 -0.18

EBITDA per Share

-0.28 -0.63 -0.4 - -1.36 -0.09 -0.09 -2.23 -0.07 -0.1 -0.13 -0.11 -0.11 -0.09 -0.1 -0.06 -0.08 -0.06 -0.09 -0.08 -0.07 0.05 -0.08 -0.11 -0.06 -0.06 -0.06 - -0.07 -0.09 0.08 - -0.08 -0.08 -0.09 - -0.09 -0.09 -0.1 - -0.1 -0.11 -0.13 - -0.14 -0.12 -0.14 - -0.13 -0.14 -0.12

ROE %

152.37 532.74 -6738.28 -6763.47 -6896.11 -7200.71 -7749.48 -581.43 -519.60 -425.35 -320.31 -334.18 -306.02 -306.30 -321.40 -274.32 -257.93 -148.92 -68.50 -54.65 -84.43 -92.86 -129.28 -127.18 -134.89 -144.57 -155.67 -93.91 -11.96 -16.39 13.94 -94.18 -143.76 -119.45 -112.42 -85.50 -103.55 -134.79 -187.52 -221.01 -187.58 -315.61 -347.53 -329.39 -371.67 -216.93 -159.56 -159.34 -22.13 -25.10 -53.85

ROA %

-248.69 -328.20 -254.26 -218.15 -254.23 -306.27 -242.93 -230.12 -231.24 -222.87 -195.28 -198.72 -185.35 -176.29 -179.46 -161.41 -155.93 -97.50 -45.46 -40.14 -60.79 -68.48 -97.14 -95.45 -93.84 -97.26 -103.05 -73.68 -22.00 -17.49 4.62 -40.84 -77.95 -70.28 -65.81 -58.88 -64.71 -79.33 -109.02 -124.97 -108.05 -114.09 -113.88 -97.37 -112.73 -90.91 -77.03 -78.48 -12.41 -13.96 -25.03

ROCE %

180.34 365.62 -6958.34 -6981.99 -7114.40 -7270.28 -7549.65 -329.14 -266.61 -261.87 -217.74 -231.90 -204.92 -200.09 -201.30 -154.44 -138.32 -112.43 -70.66 -56.21 -85.95 -94.25 -130.61 -130.92 -113.16 -121.87 -37.47 -15.57 -58.79 -52.92 -52.34 -112.37 -139.48 -119.85 -111.86 -75.61 -124.37 -149.77 -178.80 -153.89 -371.83 -403.29 -402.62 -350.00 -379.86 -188.91 -148.12 -96.29 -29.86 -27.00 -39.42

DSO

- - - - 421.1 11.8 - - - - - - - - - - - - 8.3 25.2 22.0 3.1 57.6 50.4 150.4 161.9 73.4 41.6 138.8 103.8 3.1 2.9 310.7 1102.4 220.4 263.9 214.9 189.2 91.2 48.2 75.6 83.8 134.8 18.5 51.3 18.9 18.1 15.4 11.7 20.9 -

Operating Cycle

- - - - 421.1 11.8 - - - - - - - - - - - - 8.3 25.2 22.0 3.1 57.6 45.7 134.0 79.9 36.8 55.5 182.8 95.5 2.8 3.1 316.0 579.4 65.8 263.9 214.9 189.2 91.2 51.6 76.4 83.1 141.3 19.5 44.0 16.8 19.6 24.5 26.7 25.8 -

Cash Conversion Cycle

- - - - 421.1 11.8 - - - - - - - - - - - - 8.3 25.2 22.0 3.1 57.6 45.7 134.0 79.9 36.8 55.5 182.8 95.5 2.8 3.1 316.0 579.4 65.8 263.9 214.9 189.2 91.2 51.6 76.4 83.1 141.3 19.5 44.0 16.8 19.6 24.5 26.7 25.8 -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Athersys, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
FSD Pharma FSD Pharma
HUGE
- 5743.5 % $ 69.7 M canadaCanada
Qilian International Holding Group Limited Qilian International Holding Group Limited
QLI
- -6.08 % $ 184 M chinaChina
Synthetic Biologics Synthetic Biologics
SYN
- 1.32 % $ 16.2 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
Assembly Biosciences Assembly Biosciences
ASMB
$ 34.38 2.54 % $ 385 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Corner Growth Acquisition Corp. Corner Growth Acquisition Corp.
COOL
- -0.89 % $ 114 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 207.77 0.53 % $ 10.3 B usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.37 3.95 % $ 14.9 M usaUSA
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
- 1.35 % $ 17.8 M chinaChina
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 2.81 1.81 % $ 6.93 B israelIsrael
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 66.7 0.14 % $ 12.8 B usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
NanoViricides NanoViricides
NNVC
$ 1.33 1.53 % $ 20.1 M usaUSA
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Abcam plc Abcam plc
ABCM
- - $ 4.9 B britainBritain
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
Galera Therapeutics Galera Therapeutics
GRTX
- -32.59 % $ 7.61 M usaUSA
Генетико Генетико
GECO
- - - russiaRussia
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Hepion Pharmaceuticals Hepion Pharmaceuticals
HEPA
- -18.79 % $ 39.3 K usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
BioXcel Therapeutics BioXcel Therapeutics
BTAI
$ 0.8 0.66 % $ 9.77 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 4.31 1.29 % $ 945 M britainBritain
Affimed N.V. Affimed N.V.
AFMD
- -34.95 % $ 21.5 M germanyGermany
ОЗОН Фармацевтика ОЗОН Фармацевтика
OZPH
- - - russiaRussia
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 25.08 1.12 % $ 3.19 B usaUSA
Atara Biotherapeutics Atara Biotherapeutics
ATRA
$ 9.7 3.41 % $ 122 M usaUSA
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
- -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
BeyondSpring BeyondSpring
BYSI
$ 0.72 0.81 % $ 29.6 M usaUSA
Adial Pharmaceuticals Adial Pharmaceuticals
ADIL
$ 6.22 5.34 % $ 4.16 M usaUSA
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 21.78 2.06 % $ 312 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Gracell Biotechnologies Gracell Biotechnologies
GRCL
- - $ 3.37 B chinaChina
GlycoMimetics GlycoMimetics
GLYC
- 9357.83 % $ 1.01 B usaUSA
AnaptysBio AnaptysBio
ANAB
$ 57.74 1.85 % $ 1.66 B usaUSA
Compugen Ltd. Compugen Ltd.
CGEN
$ 2.62 0.19 % $ 245 M israelIsrael
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA